10-K: Fortress Biotech Reports 2024 Results, Highlights UNLOXCYT Approval and Checkpoint Acquisition

Fortress Biotech's 2024 10-K filing details financial results, key developments including UNLOXCYT approval, and the pending acquisition of Checkpoint Therapeutics.

Summary

• Fortress Biotech's 10-K filing summarizes the company's financial performance and key events for the year ended December 31, 2024.
• The company reported operating losses of approximately $110.4 million in 2024 and has an accumulated deficit of approximately $740.9 million.
• Key developments include the FDA approval of Checkpoint Therapeutics' UNLOXCYT for cutaneous squamous cell carcinoma and Journey Medical's EMROSI for rosacea.
• Checkpoint Therapeutics entered into an agreement to be acquired by Sun Pharmaceutical Industries for $4.10 per share in cash plus a contingent value right of up to $0.70 per share upon EU approval.
• Journey Medical received FDA approval for EMROSI (Minocycline Hydrochloride Extended-Release Capsules, 40mg) in November 2024 and launched it in March 2025.
• Cyprium Therapeutics' NDA for CUTX-101 for Menkes disease was accepted for priority review by the FDA, with a PDUFA target action date of September 30, 2025.
• Helocyte is developing Triplex, a CMV vaccine, and has ongoing trials in stem cell transplant recipients, adults co-infected with CMV and HIV, and in combination with CAR T-cell therapy for NHL or ALL.
• AstraZeneca is continuing the development of CAEL-101 for AL amyloidosis, with Phase 3 trials underway.
• Urica Therapeutics transferred rights to dotinurad to Crystalys Therapeutics, receiving 35% of Crystalys' outstanding equity and a 3% royalty on future net sales.
• Mustang Bio is developing MB-101 for glioblastoma and MB-109, a combination therapy, with a Phase 1 clinical study planned.
• Avenue Therapeutics is developing IV tramadol for post-operative pain and BAER-101 for CNS disorders.
• The company faces competition in the biopharmaceutical market and relies on third parties for manufacturing and clinical trials.
• Fortress has paused dividend payments on its Series A Preferred Stock.
• The company's future success depends on acquiring or in-licensing products and product candidates and integrating them into its businesses.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company reports ongoing losses, it also highlights significant achievements like drug approvals and a potential acquisition, balancing the negative financial aspects with positive developments.

Positives

• FDA approval of UNLOXCYT and EMROSI represent significant milestones for Checkpoint and Journey, respectively.
• The pending acquisition of Checkpoint by Sun Pharma could provide a significant return on investment for Fortress.
• Cyprium's CUTX-101 receiving priority review from the FDA increases the likelihood of approval for this treatment for Menkes disease.
• Helocyte's Triplex vaccine is progressing through clinical trials for various indications, including CMV, HIV, and oncology.
• Urica's transfer of dotinurad to Crystalys allows for further development of the drug while providing Fortress with equity and royalty potential.

Negatives

• Fortress Biotech continues to experience operating losses and has a significant accumulated deficit.
• The company's ability to pay dividends on its Series A Preferred Stock is uncertain, and payments have been paused.
• The pending acquisition of Checkpoint is subject to various conditions and may not be completed.
• The company relies heavily on third parties for manufacturing and clinical trials, which could lead to delays or other issues.
• Avenue Therapeutics received a notice of intent to terminate letter from AnnJi, the licensor of AJ201, with respect to the license agreement under which Avenue was granted rights to the product candidate.

Risks

• The company's product candidates may not be successfully developed or commercialized.
• Competitors may develop treatments for the same indications, limiting the commercial opportunity for Fortress's products.
• The company may be unable to raise additional capital when needed, forcing it to delay or curtail R&D programs.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or other issues.
• The company may be subject to costly litigation for infringement of third-party intellectual property rights.
• The company's products may face generic competition and price reductions.
• The company operates in a heavily regulated industry, and future legislation could impact its operations.
• The company may be unable to meet continued listing requirements of Nasdaq, leading to delisting of its stock.

Future Outlook

Fortress Biotech expects to continue funding R&D activities through a combination of cash generated from royalties and milestones, and through additional equity or debt financings from third parties. The company anticipates that research and development costs will decrease in 2025.

Industry Context

The announcement reflects the ongoing trends in the biopharmaceutical industry, including the focus on acquiring and developing promising assets, strategic partnerships, and navigating the regulatory landscape for drug approvals. The company faces competition from other pharmaceutical and biotechnology companies, academic institutions, and research organizations.

Comparison to Industry Standards

• The report mentions competitors such as Galderma Laboratories, Almirall, Ortho-Dermatologics, Mayne Pharmaceuticals, Sun Pharma, Leo Pharma, and Arcutis Biotherapeutics in the dermatology space.
• The report does not provide a direct comparison of Fortress Biotech's financial performance to these specific companies, but it acknowledges that many competitors have greater financial and product development resources.
• The report mentions that the standard of care therapy for glioblastoma has remained relatively unchanged for the last 20 years due to the failure of novel therapies to improve survival, and there is no standard of care whatsoever for recurrent GBM.

Related Party Transactions

• The report details related-party transactions, including shared services agreements with TGTX and Journey, and the Founders Agreements with partner companies and subsidiaries.
• The report details the terms of the Founders Agreement, including the PIK dividend and equity fee structure.

Stakeholder Impact

• Shareholders: Potential for increased value through drug approvals and acquisitions, but also risk of dilution and continued losses.
• Employees: Potential for job security and growth through successful product development, but also risk of layoffs and restructuring.
• Patients: Potential for new and improved treatments for various diseases.
• Creditors: Risk of default on debt obligations if the company does not generate sufficient cash flow.

Next Steps

• Checkpoint stockholders will vote on the proposed acquisition by Sun Pharma.
• Cyprium awaits the FDA's decision on CUTX-101, with a PDUFA target action date of September 30, 2025.
• Helocyte will continue clinical trials for Triplex in various indications.
• Mustang plans a Phase 1 clinical study for MB-109.
• Avenue will pursue dispute resolution procedures with AnnJi regarding the AJ201 license agreement.

Key Dates

Keywords

Fortress Biotech, UNLOXCYT, EMROSI, CUTX-101, Checkpoint Therapeutics, Journey Medical, Cyprium, Helocyte, Avenue Therapeutics, dotinurad, MB-101, MB-109, Triplex, biopharmaceutical, Menkes disease, cutaneous squamous cell carcinoma, rosacea, gout, glioblastoma, CMV vaccine